More and more pharma companies are looking "beyond the pill" when it comes to providing care for patients, few more so than Eisai, which is developing a package of products and services in Japan ...

TOKYO, Dec 13 (Reuters) - Eisai said on Wednesday its Alzheimer's drug Leqembi will launch in Japan on Dec. 20 following its inclusion on the National Health Insurance price list. Intravenous ...

Japan’s Prime Minister Shigeru Ishiba faces a tough test in an upper house election this month as his minority government ...

TOKYO, Jan 18, 2024--- Eisai Co., Ltd. announced today that it has obtained marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for the injection formulation ...

TOKYO, Nov 29 (Reuters) - Shares in Japanese drugmaker Eisai Co headed for their biggest plunge in more than a year on Tuesday after a report that a woman in a trial of the company's Alzheimer's ...

TOKYO – Japan's health ministry has approved Leqembi, a drug for Alzheimer’s disease that was jointly developed by Japanese and U.S. pharmaceutical companies.

TOKYO, Sept 25 (Reuters) - Japan's Eisai (4523.T), opens new tab said on Monday its Alzheimer's treatment developed with Biogen (BIIB.O), opens new tab, Leqembi, was approved by the country's ...

TOKYO, Dec 13 (Reuters) - Eisai , opens new tab said on Wednesday its Alzheimer's drug Leqembi will launch in Japan on Dec. 20 following its inclusion on the National Health Insurance price list.

Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies. Skip to main content.

Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies. Skip to main content.

TOKYO – Japan's health ministry has approved Leqembi, a drug for Alzheimer’s disease that was jointly developed by Japanese and U.S. pharmaceutical companies.